Novo Nordisk breaks ground on diabetes medicine facility
Novo Nordisk Inc. has broken ground on a new $1.8 billion diabetes medicine production facility in Clayton, N.C. The 833,000-square-f00t Clayton facility will make active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future GLP-1 and insulin medicines.